MedTrace Logo

Metformin Plus Paclitaxel for Metastatic or Recurrent Head and Neck Cancer

NCT01333852 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2015-01-27

No results posted yet for this study

Summary

Metformin plus paclitaxel for recurrent or metastatic head and neck cancer: a randomized phase II trial

Conditions

Interventions

DRUG

metformin up to 2500mg/d

metformin up to 2500mg/d

DRUG

paclitaxel 175mg/m² q21d

paclitaxel 175mg/m² q21d

DRUG

placebo

placebo

Sponsors & Collaborators

  • Fundação de Amparo à Pesquisa do Estado de São Paulo

    collaborator OTHER_GOV

  • University of Campinas, Brazil

    collaborator OTHER

  • Lucas Vieira dos Santos

    lead OTHER

Principal Investigators

  • Lucas V dos Santos, MD · HCB

  • Jose BC Carvalheira, MD, PhD · University of Campinas, Brazil

  • Andre L. Carvalho, MD, PhD · HCB

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-02-28
Primary Completion
2014-01-31
Completion
2014-04-30

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01333852 on ClinicalTrials.gov